Evaluate the Correlation of NIRS, ABI, Exercise, baPWV and Albuminuria With Peripheral Artery Occlusion Disease (PAD) and Other Atherosclerosis Outcomes

December 17, 2017 updated by: Chang Gung Memorial Hospital

To Evaluate the Correlation of Near Infrared Spectroscopy, ABI, Exercise Test, baPWV and Microalbuminuria With Peripheral Artery Occlusion Disease and Other Atherosclerosis Outcome

By utilizing Near infrared spectroscopy (NIRS), the local blood flow, tissue oxygenation (StO2), and recovery time of ischemic leg; can be determined. It is reasonable to standardize an easy, simple and safe Active Pedal Plantarflexion (APP) exercise test working load which can achieve the lowest StO2 and other parameters in ischemic leg through observation of NIRS. After standardized of an effective APP test, a determination of a new cutoff value of resting ABI in diagnosing PAD can probably be searched. Analysing the correlation of baPWV with ABI, atherosclerosis risk factors and parameters with atherosclerosis outcome. Observation the Sequential changes of baPWV, ABI and microalbuminuria after managing the atherosclerosis risks, and analyze their influence on the outcome of PAD, coronary artery disease(CAD) and cerebral vascular disease(CVA) outcomes.

Study Overview

Detailed Description

Exercise testing by Active Pedal Plantar flexion:

The investigators plan to collect 140 cases:

  1. Healthy subjects with no apparent atherosclerotic risk [< 65 y/o, no diabetic mellitus (DM), no hypertension, or no hyperlipidemia, not obese, not current smoker, no smoking history >10 years] 4(n=5)
  2. Patients at risks (e.g. hypertension, hyperlipidemia) (n=5) but without DM,
  3. Type 1 and Type 2 DM patients with normal ABI( >1.0)and normal Toe-brachial index (TBI) (> 0.6) without intermittent claudication(by Edinburgh claudication questionnaire), nor PAD diagnosis (n= 10)
  4. DM normal ABI>1.0 and normal TBI (> 0.6) with suspected symptoms (intermittent claudication, non healing ulcer) (n=10),
  5. DM normal or borderline ABI( >1, 0.91~0.99) but low TBI (< 0.6), or with suspected symptoms (intermittent claudication, non healing ulcer) (n=20),
  6. DM patients with borderline ABI (0.91-0.99) (n=50) with or without leg symptoms,
  7. DM patients abnormal Low ABI (<0.9) (n=30) with or without leg symptoms,
  8. DM patients abnormal high ABI (> 1.3) (n=10)with or without leg symptoms, Post-exercise ABI with APP, and NIRS examination during APP exercise test will be performed.

The investigators also plan to collect 500 cases of nonpregnant, ≥ 40 years old DM patients, obtained baPWV and the resting ABI by oscillometric device (Omron colin, Japan). The investigators will apply this novel technique to assess the extent of arteriosclerosis and atherosclerosis by oscillometric device in our DM patient without PAD (ABI >0.9).

Collect baseline characteristics and follow up annual data: Age, sex, body weight, height, BMI, waist circumferences, history of smoking (ex-smoker, current), coexisting hypertension, hyperlipidemia, DM duration, presence of chronic DM complications of neuropathy, retinopathy (by fundus camera), nephropathy (cr, estimate glomerular filtration rate(eGFR), proteinuria, microalbuminuria). The biochemistry data involving atherosclerotic risk including: systolic blood pressure, diastolic pressure, mean pulse pressure, HbA1c, total cholesterol, LDL-Cholesterol(LDL-C), HDL-Cholesterol(HDL-C), triglyceride, creatinine, microalbuminuria,, high sensitive C-Reactive Protein (hs CRP), baseline EKG all will be collected. All the above data will be followed up annually for 3 years to analyze the correlation of progressive change of baPWV, ABI and microalbuminuria with the atherosclerosis event and mortality.

Study Type

Observational

Enrollment (Anticipated)

650

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Nonpregnant & ≥ 20 years old type1 and type 2 diabetic patients

Description

Inclusion Criteria:

  • type 1 diabetic patients
  • type 2 diabetic patients

Exclusion Criteria:

  • Pregnancy
  • Critical limb ischemia (gangrene change)
  • A permanent pacemaker implant
  • Systolic BP ≥ 200 mmHg or diastolic BP ≥100 mmHg
  • Symptomatic orthostatic blood pressure drop ≥ 20 mmHg
  • Severe critical aortic stenosis
  • Acute medical illness, fever, systemic infection
  • Uncontrolled atrial or ventricular dysrhythmias
  • Uncontrolled sinus tachycardia≥ 120/min
  • Peripheral venous insufficiency, thrombosis or thrombophlebitis
  • Those who has factors known to influence the PWV
  • The brachial-ankle PWV could not be measured on the right and left sides
  • Orthopedic condition (ankle or foot) that cannot perform an active pedal plantar flexion (APP) technique (arthritis, hemiparesis, balance impairment etc.)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
diabetic mellitus patients

Measure the brachial-ankle pulse wave velocity (baPWV) and the resting ankle-brachial index(ABI) of pre-exercise and post-exercise by the oscillometric (Omron Colin co.).

And follow up for 3 years to identify of the correlation with PAD outcome.

fast measurements of the brachial-ankle pulse wave velocity (baPWV) and the resting ankle-brachial index(ABI) with the oscillometric method (Omron Colin co, Japan)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Define the correlation between NIRS and ABI
Time Frame: 12 month
Analyse the correlation of NIRS with different ABI
12 month
Defined APP exercise ABI criteria for PAD diagnosis
Time Frame: 12 month
Design APP exercise with effective working load to defined ABI criteria for PAD diagnosis
12 month
The correlation of changes of baPWV and the outcome of PAD
Time Frame: 12,24 and 36 months
Analyse the sequential changes of baPWV and the outcome of PAD
12,24 and 36 months
The correlation of changes of exercise ABI and the outcome of PAD
Time Frame: 12,24 and 36 months
Analyse the sequential changes of exercise ABI and the outcome of PAD
12,24 and 36 months
The correlation of changes of albuminuria and the outcome of PAD
Time Frame: 12,24 and 36 months
Analyse the sequential changes of albuminuria and the outcome of PAD
12,24 and 36 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ng Soh Ching, MD, Chang Gung Memorial Hospital, Keelung

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2016

Primary Completion (Anticipated)

April 30, 2019

Study Completion (Anticipated)

April 30, 2019

Study Registration Dates

First Submitted

May 4, 2017

First Submitted That Met QC Criteria

December 17, 2017

First Posted (Actual)

December 19, 2017

Study Record Updates

Last Update Posted (Actual)

December 19, 2017

Last Update Submitted That Met QC Criteria

December 17, 2017

Last Verified

May 1, 2017

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes

3
Subscribe